SAB Biotherapeutics Inc (SABS) Stock Forecast & Price Target
SAB Biotherapeutics Inc · NASDAQ
$3.48-0.15 (-4.13%)
15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering SAB Biotherapeutics Inc, 9 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.29 sits 253% above the current $3.48. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-0.95 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Strong Buy
Strong Buy00%
Buy9100%
Hold00%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to SAB Biotherapeutics Inc.
As of Sep, 9 of 9 firms rate SABS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SABS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.39 – $-0.19 · 5 analysts · -34% YoY
Next period, 5 analysts expect SAB Biotherapeutics Inc to earn $-0.27 a share (range $-0.39 – $-0.19), versus $-0.41 a year earlier. Full-year consensus is $-1.16, growing to $-0.95 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 5 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $62.5K next year.
Top analysts covering SAB Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SABS.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$15.00+331.0% to target
Overall win rate
53%
+ Follow
#2
Keay Nakae
Chardan Capital · Rank #89
Buy
$16.00+359.8% to target
Overall win rate
43%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$11.00+216.1% to target
Overall win rate
43%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #307
Buy
$14.00+302.3% to target
Overall win rate
37%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$10.00+187.4% to target
Overall win rate
23%
+ Follow
SABS stock forecast FAQ
What is SABS's average 12-month price target?+
The 7 analysts with a live target average $12.29 for SAB Biotherapeutics Inc over the next 12 months, ranging from a $16.00 high to a $10.00 low.
Is SABS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 9 analyst ratings, 9 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SABS?+
The Street-high target is $16.00 (Chardan Capital), and the Street-low is $10.00 (HC Wainwright & Co.). The average of all 7 active targets is $12.29.
How many Wall Street analysts cover SABS?+
9 analysts have an active rating on SAB Biotherapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering SABS?+
Among analysts who currently cover SABS, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $15.00 target.
What is SAB Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.39 – $-0.19) across 5 analysts. Full-year EPS is projected at $-1.16, rising to $-0.95 the following year.
How much revenue is SAB Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $62.5K next year.
Have analysts been upgrading or downgrading SABS lately?+
As of Sep, 9 of 9 firms rate SABS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SABS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
